GALECTIN THERAPEUTICS INC — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On July 31, 2026, Galectin's Chairman Richard Uihlein converted $105.8M in debt ($91.0M principal + $14.8M accrued interest) into 34,376,167 shares of common stock, eliminating five of six credit facilities and strengthening the balance sheet. Concurrently, the company submitted a registrational Phase 3 protocol to FDA for belapectin in MASH cirrhosis with portal hypertension (primary endpoint: composite liver outcome); NAVIGATE Phase 2b/3 data presented at AASLD showed belapectin-treated patients had 15.9% placebo-adjusted improvement in ANTICIPATE-NASH CSPH risk (p=0.04). Q3 2026 cash position: $11.7M with $10M additional credit line available; company projects funding through June 2027.
Why this rating
Debt elimination ($105.8M ≈ 97% of market cap) dramatically improves solvency and runway; Phase 3 filing represents key inflection. Material positive for $109M company.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.04% over 4 hrs, n=508). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $3.04 | +10 min · unknown $3.06 ▲ 0.82% | +30 min · unknown $3.08 ▲ 1.32% | +1 hr · unknown $3.12 ▲ 2.80% | +4 hrs · unknown $2.93 ▼ 3.46% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.